Research output: Contribution to journal › Article › peer-review
Nitasha Singh, Val Lewington
Original language | English |
---|---|
Pages (from-to) | 453-457 |
Number of pages | 5 |
Journal | Clinical Medicine |
Volume | 17 |
Issue number | 5 |
DOIs | |
E-pub ahead of print | 1 Oct 2017 |
Additional links |
Molecular radiotheragnostics in thyroid_SINGH_Published1October2017_GREEN VOR
Molecular_radiotheragnostics_in_thyroid_SINGH_Published1October2017_GREEN_VOR.pdf, 170 KB, application/pdf
Uploaded date:24 Oct 2017
Version:Final published version
Molecular radiotheragnostics directly links nuclear medicine diagnostic imaging to therapy. The imaging study is used to detect a specific molecular target associated with a disease process. A radiotherapeutic molecule with a similar biodistribution to the diagnostic agent can then be used to deliver targeted therapy. Molecular radiotheragnostics have been applied to manage both benign and malignant thyroid disease since the 1940s. The specific molecular pathway targeted is the sodium/iodide symporter (NIS) located on the basolateral membrane of the thyroid follicular cell. Radiolabelling of iodide or a similar ion allows targeting of the NIS system with radiopharmaceuticals for imaging (123I-radioiodine and 99mTc-pertechnetate) and treatment (131I-radioiodine) by virtue of their gamma ray and beta-particle emissions, respectively. Scintigraphic imaging directly guides 131I-radioiodine treatment planning to maximise therapeutic benefit while minimising adverse reactions, in a personalised medicine approach.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454